M22-418 Atogepant-Botox Combination Study
ClinicalTrials.gov NCT05216263
Research payments
$98,417
Through program year 2024, $98,417 in research payments was reported against M22-418 Atogepant-Botox Combination Study, across 28 payments, paid by AbbVie, Inc..
- Paid by
- AbbVie, Inc.
- ClinicalTrials.gov
- NCT05216263
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $98,417 | 28 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Atul Patel Overland Park, KS Named on 1 payment
- Sait Ashina New York, NY Named on 1 payment
- Umer Najib Morgantown, WV Named on 1 payment
- Teshamae Monteith Miami, FL Named on 1 payment
- Simon Fishman Alexandria, VA Named on 1 payment
- Charles Argoff Albany, NY Named on 1 payment
- Laszlo Mechtler Amherst, NY Named on 1 payment
- Daniel Harnsberger Chattanooga, TN Named on 1 payment
- John Rothrock Fairfax, VA Named on 1 payment
- Hessam Aazami Canoga Park, CA Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.